If you are looking up when to take NAD+, no human study proves one time of day works best. Your schedule comes from your prescribing clinician and the label on your pharmacy vial.
As of October 17, 2026, the day this article was written, database checks found no human trial comparing morning and evening NAD+ injections. Those checks covered PubMed and 267 ClinicalTrials.gov records. Still, database searches cannot rule out unpublished clinic records.
Because no human trial favors one hour over another, NAD+ injection timing starts with your prescription directions. Mouse studies and clinic routines do not establish the best time for a human NAD+ injection.
When to take NAD+: morning or night?
Mouse cell-clock research helps explain why timing is studied, but it does not set a human injection schedule. Those experiments tracked nicotinamide adenine dinucleotide (NAD+), a helper molecule that cells rely on for energy and repair.
A 2009 mouse study in Science and a companion 2009 Science paper showed that cellular NAD+ cycles on a 24-hour rhythm. That cycle runs through the salvage pathway, a recycling loop where the enzyme NAMPT rebuilds NAD+ in mouse cells.
Researchers later tested timed NAD+ shots in animals. A 2023 mouse study in Nature Communications gave abdominal NAD+ injections to obese mice before their active or rest phase. Active-phase shots improved several metabolic and liver-clock measures more than rest-phase shots, while other responses did not depend on timing.
Still, a mouse active phase does not map onto a person's morning or bedtime routine. Rodent data cannot tell a person which hour on the clock to choose for a prescribed injection.
Does NAD+ keep you awake at night?
Many patients ask does NAD+ keep you awake if a dose is taken later in the day. Several human studies have collected sleep data around NAD+ use, though none proves whether evening shots cause insomnia.
A 2026 Frontiers in Aging review followed six clients getting intravenous (IV, into a vein) NAD+ and eight getting nicotinamide riboside (NR). Clients received drips at the same clock time for four days while wearing OURA sleep rings and completing 30-day sleep surveys. The published paper did not report a numerical sleep result or compare morning and evening dosing.
An earlier 2024 addiction-treatment report interviewed 50 patients given IV drips combining NAD+ with amino acids and B vitamins. Self-reported sleep shifted from 6.28 to 7.34 hours, a non-significant change. Because the drip mixed several ingredients without a control group, it cannot isolate what NAD+ alone does to sleep.
As of October 17, 2026, the day this article was written, the original UMIN registry reports completed follow-up in 20 adults. Participants were given repeated subcutaneous (under the skin) NAD+ with lidocaine. Registry results were posted September 14, 2026, before public disclosure on September 15.
The record reports larger sleep-score changes in participants with baseline sleep complaints than in those without. However, the uncontrolled design cannot isolate NAD+'s effect or establish a preferred injection time.
A 2025 U.S. injection trial on ClinicalTrials.gov also lists a 10-day sleep scale for subcutaneous, intramuscular (into a muscle), and IV-push NAD+. That record has no posted results. Oral trials of precursors like NR or nicotinamide mononucleotide (NMN) — ingredients the body converts into NAD+ — cannot settle injection sleep timing.
Taking NAD+ before or after a workout
The October 17, 2026 searches identified no human trial comparing NAD+ injections before versus after a workout. None of the human IV studies or registered injection trials assigns doses around exercise sessions.
A 2019 human IV pilot in Frontiers in Aging Neuroscience studied 11 men aged 30 to 55. It measured elapsed infusion time, not time of day. Eight men received a six-hour NAD+ drip and three received saline while researchers sampled blood and urine over eight hours.
Measured blood NAD+ did not rise significantly during the first two hours. A significant increase appeared at six hours and remained at eight hours. Our breakdown of the human NAD+ IV study covers those chemical measurements in detail.
Those samples do not establish a subcutaneous half-life, which is the time it takes the level in the blood to fall by half. They also do not measure felt energy or set a pre-workout window.
| Timing question | Evidence available | What remains unanswered |
|---|---|---|
| Morning vs. evening | Mouse clock studies and a 2023 mouse active-vs-rest injection study | No human morning-versus-evening injection trial identified in the October 17, 2026 searches |
| Sleep and wakefulness | Wearable and survey collection in IV records, a mixed-IV report, and registered injection studies | Whether NAD+ injections cause insomnia or improve sleep |
| Before vs. after exercise | Human IV studies and an injection trial built for other questions | Whether injecting before or after workouts changes recovery or performance |
| Blood chemistry timing | Plasma and urine samples over 8 hours during a 6-hour IV drip in 11 men | How long a subcutaneous shot lasts or affects felt energy |
How side effects and product quality fit into timing
The available IV reports describe infusion reactions but do not show whether clock time changes their likelihood. The 2019 six-hour IV pilot observed no adverse events in its eight treated men. Faster infusions in commercial clinic records looked very different.
In the 2026 review, all six NAD+ IV clients reported moderate to severe symptoms. These included cramping, diarrhea, nausea, vomiting, faster heart rates, throat pain, congestion, and chest pressure. Symptoms stopped when the drips ended after an average of 97 minutes.
Because those six clients adjusted their own IV drip rates, their records cannot predict reaction rates for a subcutaneous prescription. Ingredient suitability is a separate safety issue from injection timing.
An October 30, 2024 FDA compounding notice reported that some compounders used food-grade NAD+ to make IV products. Patients had "severe chills, shaking, vomiting and fatigue with some requiring medical treatment," reactions the FDA called "consistent with excessive levels of endotoxins".
Picking a morning schedule will not fix an unsuitable ingredient, a safety topic covered in NAD+ injection side effects. A prescribed path provides an identifiable prescriber and dispensing pharmacy to contact about the medication's label, ingredient questions or a reaction. That accountability does not guarantee that preparation problems cannot occur.
FDA status and how your prescriber sets your schedule
The October 17, 2026 FDA database checks identified no approved NAD+ injection label supplying a standard morning or evening schedule. Active-ingredient searches of the Drugs@FDA database return no matches for NAD+. As the FDA's compounding Q&A states, compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality before marketing.
NAD+ prescribed through Promise is dispensed as a compounded medication by a licensed U.S. compounding pharmacy. The compounded formulation is not FDA-approved.
On the May 14, 2026 Section 503A bulk list, Nicotinamide Adenine Dinucleotide (NAD) and reduced NADH sit separately in Category 1 under evaluation. A distinct beta disodium salt trihydrate entry sits in Category 3 for substances nominated without adequate support.
As the FDA's Section 503A policy page explains, Category 1 is an interim evaluation category rather than an approval. Even though no NAD+ injection is FDA-approved, a licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies.
Your clinician and dispensing pharmacy set your schedule alongside how providers approach NAD+ injection dosage and whether NAD+ fits your goals. If sleep changes or other symptoms appear, check with your prescribing clinician before adjusting your routine.
